Clinical Trials on Luminal B

Total 6001 results

Spanish Breast Cancer Research Group
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Faculty...

Completed

Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients (EFIK)

Breast Cancer | Luminal B

Spain
University Hospital, Akershus
Vestre Viken Hospital Trust; Novartis

Recruiting

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB)

Breast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast Cancer

Norway
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
Second Affiliated Hospital, School of Medicine,...
GeneCast Biotechnology Co., Ltd.

Recruiting

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Luminal B/HER2-negative Breast Cancer

China
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE)

Breast Cancer | Triple Negative Breast Cancer | Luminal B

Belgium
Hospital General Universitario Gregorio Marañon

Terminated

CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.

Triple Negative, HER2+, Luminal B Breast Tumors (Stages II-III)in Female Patients

Spain
Institut Curie

Active, not recruiting

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Triple Negative Breast Cancer | Pediatric Cancer | Metastatic Uveal Melanoma | Luminal B Breast Cancer

France
Samsung Medical Center

Completed

The Lamina Cribrosa (LC) Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)

The Lamina Cribrosa and Optic Nerve Head Changes
Peking University People's Hospital

Unknown

Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer

Lymph Node Metastases | Immune Microenvironment | Luminal A

China
Reproductive Medicine Associates of New Jersey

Completed

Evaluation of Discarded Laboratory Pathological Specimens and Media

Non-viable Oocytes | Extra Spermatozoa | Seminal Fluid | Granulosa Cells | Serum | Follicular Fluid | Conditioned IVF Media

United States
University Hospital, Grenoble

Recruiting

Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (Néo-APBI-01)

Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast Cancer

France
Athenex, Inc.

Recruiting

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2)

B-cell Lymphoma | CLL/SLL | ALL, Childhood | DLBCL - Diffuse Large B Cell Lymphoma | B-cell Leukemia | NHL, Relapsed, Adult | ALL, Adult B Cell

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
Lapo Alinari

Recruiting

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC... and other conditions

United States
Università Vita-Salute San Raffaele
IRCCS San Raffaele; Associazione Italiana per la Ricerca sul Cancro

Not yet recruiting

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer (FESTA)

Breast Cancer Female | Lobular Breast Carcinoma | Luminal A Breast Cancer | PET/MRI | Axillary Lymphadenopathy
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Ohio State University Comprehensive Cancer Center

Recruiting

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

United States
University of Chicago
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Lymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Dana-Farber Cancer Institute
Bayer; AbbVie

Active, not recruiting

Copanlisib Plus Venetoclax in R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Curocell Inc.

Recruiting

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

High-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell Lymphoma

Korea, Republic of
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Amgen

Active, not recruiting

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Taiwan, Australia
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Institute of Hematology & Blood Diseases Hospital
Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

Unknown

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

China
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Vanderbilt-Ingram Cancer Center
Kite, A Gilead Company

Active, not recruiting

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Diffuse Large B-cell Lymphoma | Large B-cell Lymphoma

United States
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Autolus Limited

Completed

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom
Molecular Templates, Inc.

Terminated

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma | Non-hodgkin Lymphoma,B Cell

United States
Ottawa Hospital Research Institute

Unknown

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

B Cell Non-Hodgkin's Lymphoma | B Cell Lymphocytic Leukemia
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States
Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Patrick C. Johnson, MD
AstraZeneca

Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditions

United States
Memorial Sloan Kettering Cancer Center
Takeda

Recruiting

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

B-Cell Lymphoma | Large B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | Mediastinal Large B-cell Lymphoma | High-grade B Cell Lymphoma

United States
Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Diffuse Large B-cell Lymphoma | High-Grade B-cell Lymphoma

United States, Spain, Australia, Denmark

Clinical Trials on Luminal B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations